Data from Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer?
Year: 2023
Type: other
Abstract: Anaplastic lymphoma kinase (ALK) gene rearrangements are found in approximately 5% of non–small cell lung carcinoma patients and confer sensitivity to ALK inhibitors such as crizotinib. The particular ALK fusion expressed may have an impact on protein stability and sensitivity to crizotinib, and this may underlie the heterogeneity in responses observed in the clinic. Clin Cancer Res; 18(17); 4479–81. ©2012 AACR.
Authors: Adam S. Crystal, Alice T. Shaw
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361960108